Ziopharm Oncology (ZIOP)

Company Description

ZIOPHARM Oncology (ZIOP) is a second-generation gene therapy company focused on the development of new cancer treatments with a laser focus on the red-hot immune oncology (I/O) sector. ZIOP licensed its gene expression control technology from synthetic-biology innovator Intrexon for use in the development of DNA-based oncology treatments. Under an exclusive channel partner agreement, the two companies have collaborated to develop a tightly controlled system that injects a gene-expression package into tumors to express the anti-tumor cytokine interleukin-12 (IL-12), but only when patients take a pill that contains a ligand to activate the IL-12 gene. When the patient stops taking the pill, IL-12 expression stops, allowing for specific dosing for a set time. Expression is controlled by Intrexon’s proprietary biologic switch known as the RheoSwitch. The ability to administer or withdraw the pill to control gene expression is a key safety benefit.

 

COMPANY ADDRESS
1 First Avenue
Parris Building, #34
Navy Yard Plaza
Boston, MA 02129
United States

COMPANY PHONE
(617) 259-1970

COMPANY WEBSITE


Get BioInvest's perspective on Ziopharm's CEO

Latest Company News

What's Happening To These Stocks? - Sonus Networks, Inc. (SONS), ZIOPHARM ... Post Analyst - 11 hours ago Turning to ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), its shares were trading at $7.44 a gain of $0.35, on the trading floor. [...]
Thu, Apr 27, 2017 6:56:00 PM, Continue reading at the source
ZIOPHARM Oncology, Inc. (ZIOP) Closed its Previous Trade at $7.44 TopChronicle - 17 hours ago The share of ZIOPHARM Oncology, Inc. (ZIOP) currently has a value of $7.44 while the company's 52 week low is at $4.45, the shares dropped to the 52 week low on 07/25/16. ZIOPHARM Oncology (ZIOP) Getting Somewhat Favorable Media Coverage, Analysis Shows - The Cerbat Gem [...]
Thu, Apr 27, 2017 1:03:00 PM, Continue reading at the source
Buy or Sell? Average Brokerage Ratings on ZIOPHARM Oncology, Inc. (ZIOP), DISH ... StockNewsJournal - Apr 26, 2017 Investors who are keeping close eye on the stock of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) established that the company was able to keep return on investment at -146.19 in the trailing twelve month while Reuters data showed that industry's average ... Zacks Investment Research Lowers ZIOPHARM Oncology Inc. (ZIOP) to Sell - The Cerbat Gem Stock Target Review on ZIOPHARM Oncology Inc (NASDAQ:ZIOP) - Aiken Advocate [...]
Wed, Apr 26, 2017 7:18:00 PM, Continue reading at the source
ZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate ... Yahoo Finance - Apr 24, 2017 BOSTON, April 24, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will host a conference call and webcast slide presentation on Monday, May 1, 2017 ... ZIOPHARM Oncology Inc. (ZIOP) Sees Large Decline in Short Interest - Transcript Daily Does $6.79 justifies ZIOPHARM Oncology, Inc. (ZIOP) shares? - TopChronicle [...]
Mon, Apr 24, 2017 10:52:00 AM, Continue reading at the source
ZIOPHARM Oncology Inc (ZIOP) Moves Higher on Volume Spike for March 10 Equities.com - Mar 10, 2017 ZIOPHARM Oncology Inc (ZIOP) traded on unusually high volume on Mar. 10, as the stock gained 7.82% to close at $6.89. On the day, ZIOPHARM Oncology Inc saw 1.97 million shares trade hands on 8,502 trades. Considering that the stock averages only a ... [...]
Fri, Mar 10, 2017 10:30:00 PM, Continue reading at the source
Company Update (NASDAQ:ZIOP): ZIOPHARM Oncology Inc. Announces 4Q:16 Financial ... Smarter Analyst - Feb 16, 2017 ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced financial results for the fourth quarter ended December 31, 2016, and provided an update on the Company's recent activities. [...]
Thu, Feb 16, 2017 9:34:00 PM, Continue reading at the source
The Reason Behind ZIOPHARM Oncology Inc.'s 11% Gain Motley Fool - Nov 10, 2016 Shares of ZIOPHARM Oncology (NASDAQ:ZIOP), a clinical-stage biopharmaceutical company focused on the development of various immunotherapeutic cancer treatments, surged as much as 11% during Thursday's trading session after the company ... Stock Update (NASDAQ:ZIOP): ZIOPHARM Oncology Inc. Reports Third Quarter 2016 ... - Smarter Analyst [...]
Thu, Nov 10, 2016 8:02:00 PM, Continue reading at the source
Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics Motley Fool - Nov 3, 2016 And although it hasn't been as closely associated with CAR-T as Juno Therapeutics, Ziopharm Oncology (NASDAQ:ZIOP) is part of a collection of entities (including Intrexon, Merck, and MD Anderson) developing a therapeutic pipeline in the same class, ... ZIOPHARM Announces Four Presentations at the 2016 ASH Annual Meeting - GlobeNewswire (press release) [...]
Thu, Nov 03, 2016 3:41:00 PM, Continue reading at the source
Better Buy: Ziopharm Oncology, Inc. vs. Intrexon Corporation Motley Fool - Oct 14, 2016 The close relationship between Ziopharm Oncology (NASDAQ:ZIOP) and Intrexon (NYSE:XON) hasn't gone unnoticed by investors -- in fact, it's impossible to overlook since the latter is likely responsible for a majority of the former's $660 million market cap. [...]
Fri, Oct 14, 2016 7:41:00 PM, Continue reading at the source
Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc. Motley Fool - Sep 24, 2016 Clinical-stage biotechs Ziopharm Oncology (NASDAQ:ZIOP) and Alnylam Pharmaceuticals (NASDAQ:ALNY), for example, have both suffered in 2016. [...]
Sat, Sep 24, 2016 11:48:00 AM, Continue reading at the source